Top Telehealth Companies With Best Stability & Growth (968)

Strong Market Position & Advantage: The platform reports a community of 3+ million members and coverage of more than 85% of U.S. physicians, reinforcing strong network effects and defensible reach. This verified penetration underpins commercial access to prescribers across its marketing, hiring, and workflow offerings.

Innovation-Driven Growth: Engagement momentum is evident with workflow active prescribers up 30%+ year over year and AI Search queries up 25%+ quarter over quarter. Management is investing in AI-driven workflow tools (e.g., Doximity Ask) to deepen usage and expand monetization.

Investor Backing & Capital Strength: The board authorized up to $500 million in additional share repurchases during FY2026, signaling balance‑sheet strength and long‑term confidence. Capital return alongside continued product investment suggests room to navigate near‑term variability.

Profitability: Profitability is highlighted as first achieved in 2023 and sustained thereafter, with the company also describing itself as cash‑flow positive. These signals point to durable unit economics and financial health.

Strong Revenue Growth: Revenue is described as growing quickly over multiple years with momentum expected to continue, while efficiency benchmarks such as the Rule of 40 have been surpassed. Together, these indicators suggest efficient, scalable growth.

Strategic Partnerships: New integrations and channels—such as embedded real‑time booking on Yelp, Healthgrades, and Google’s Gemini, along with payer partnerships—are expanding distribution and reinforcing growth. These collaborations broaden patient access points and help providers secure bookings.

Strong Revenue Growth: Available information indicates revenue reaccelerated in 2024 to an annualized level around $600M, propelled overwhelmingly by the GLP‑1‑centered Ro Body program. This momentum emerged in late 2023 and continued through 2024.

Strategic Partnerships: Pharma integrations expanded with Eli Lilly offering Zepbound vials via Ro in December 2024 and Novo Nordisk naming Ro as a telehealth partner for the nationwide Wegovy pill launch in 2026. These arrangements broaden access to on‑label GLP‑1s and fortify supply channels.

Market Expansion: Manufacturer affordability and subscription initiatives in 2025–2026 explicitly included partners like Ro, widening access points and supporting patient acquisition and retention in obesity care. The addition of the Wegovy pill via telehealth increased the addressable market beyond injectables.

Investor Backing & Capital Strength: Back-to-back Series D ($118M, Feb 2026) and Series E ($100M, May 2026) at step-up valuations to roughly $1.35B and $2.74B point to ample runway and strong investor confidence. Participation from firms such as Index Ventures, Kleiner Perkins, Sequoia, Thrive, Founders Fund, Redpoint, and Kaiser Permanente Ventures underscores capital strength.

Strong Revenue Growth: Company disclosures cite approximately $200M in gross annual recurring revenue with revenue more than doubling for five consecutive years, including over 130% year-over-year growth noted in early 2026. Nearly 800 customers and millions of covered members are also cited as evidence of expanding commercial scale.

Strategic Partnerships: New collaborations in 2026 with Priority Health and Atlantic Health expand distribution into health plan and regional employer channels. Priority Health separately confirmed the partnership and product launch.

Investor Backing & Capital Strength: Large late-stage financing, including a $100M Series C in May 2026 that brought total funding to about $215M, signals ample runway and external confidence. Coverage of a valuation step-up around $1.75B and participation from prominent firms reinforces balance-sheet strength.

Strategic Partnerships: In‑network status with major insurers and expanding relationships with health plans, employers, and health systems are emphasized across recent materials. Access to 160M–200M+ covered lives and significant health‑system referrals indicate robust commercialization channels.

Strong Revenue Growth: Recognition on the 2026 Inc. 5000 and statements of year‑over‑year acceleration point to rapid top‑line expansion. Directional revenue signals align with sharp increases in patients served and provider capacity.

Investor Backing & Capital Strength: The company closed a $55M Series B in May 2025, bringing total capital raised to roughly $125M to fund service and technology expansion. Participation from firms such as General Catalyst, a16z, GV, and Accel indicates the capacity to finance multi‑state rollouts.

Market Expansion: Operations expanded from 5 states in 2023 to 18 by May 2025, with Care+/Preventive Care+ home visits reaching about 25 states by February 19, 2026. Announced plans in 2025 also targeted 22 states that summer, signaling sustained footprint growth.

Strong Revenue Growth: As of May 15, 2025, coverage described revenue growing six‑fold year over year alongside an 18‑state footprint. Company materials also point to surging visit volumes, including Q4 2025 exceeding the combined total of 2022–2024.

Strong Revenue Growth: Repeated Inc. 5000 recognition through 2025–2026 points to sustained multi‑year top‑line expansion. This ongoing external acknowledgement aligns with signals of continued growth momentum.

Market Expansion: The acquisition of Joshin in 2025 extends the platform into integrated neurodiversity and disability support, broadening the company’s reach beyond its historical software footprint. Partnerships and integrations with adjacent platforms further widen distribution and cross‑sell opportunities.

Innovation-Driven Growth: Multiple 2026 launches—Session Note AI, an AI Dashboard for ABA operations, and BillAI—illustrate a rapid product cadence aimed at deepening adoption and upsell. This pace of releases underscores continued investment in AI and workflow automation.

Strong Revenue Growth: Independent estimates indicate annualized gross revenue roughly doubled in 2024, with external rankings highlighting multi‑year acceleration. Company disclosures of 10M+ completed sessions reinforce the scale consistent with rapid topline expansion.

Market Expansion: Therapy and psychiatry services extended to all 50 states, alongside a provider network reported in the 21,000–23,000+ range and millions of completed sessions. Regularly updated insurer rosters and health‑system channels broaden access across regions.

Strategic Partnerships: Relationships span most major commercial insurers and selected government programs, with ongoing additions and renewals noted on patient‑support and partner pages. Enterprise collaborations with large platforms and health systems signal durable channel growth and referral flow.

Investor Backing & Capital Strength: Funding is described as a $15.5M Series A in October 2025 led by Costanoa Ventures with participation from Town Hall Ventures and Khosla Ventures, following an earlier 2024 seed. The round is explicitly framed to scale access, hiring, product, and market expansion.

Market Expansion: Go‑to‑market activity is described as expanding beyond New York into states like New Jersey and Ohio with active deployments and continued outreach into 2025–2026. Company materials and public profiles reference multi‑state operations and ongoing hiring to broaden footprint.

Strategic Partnerships: School‑district collaborations are highlighted (e.g., Millville Public Schools) alongside positioning as a school‑centered therapy platform aimed at K‑12 administrators and counselors. The model integrates school‑based referrals with insurer coverage, indicating partnership‑driven growth.

Product Line Growth: New capabilities launched in 2024–2026—including agent-to-agent clinical collaboration, GenAI-powered wellness and behavioral health agents, and the Navigator end-to-end platform—demonstrate continued investment and widening solution scope. The 2024 rebrand and unified suite signal a broader footprint designed for deeper partner deployments.

Strategic Partnerships: A collaboration with Google Cloud on generative AI, multiple Gartner Hype Cycle recognitions, and added partners such as Protera MSK and FCamara broaden capabilities and routes to market. These alliances indicate an ecosystem approach that can accelerate distribution and adoption across regions and use cases.

Market Expansion: A consistently cited footprint of 26–28 million covered lives across the U.S. and Latin America and a 2026 engagement with a national employer-focused care-management organization point to ongoing commercial traction. International go-to-market activity in Brazil further supports geographic growth.

Investor Backing & Capital Strength: New capital of a $72M Series C on May 29, 2025 (bringing total funding to roughly $162M) is confirmed by the company and independent outlets, signaling capacity to scale. Feedback suggests this funding underpins continued product and market build-out.

Market Expansion: Expansion beyond the U.S., including a UK launch in December 2025, shows growing geographic reach. Third-party confirmation from Zurich UK highlights at-scale deployment to over 3 million Life Protection customers in a new market.

Strategic Partnerships: Large-scale distribution agreements with blue-chip insurers such as Zurich UK and Transamerica materially increase potential reach. These relationships embed the platform within established carrier channels across multiple regions.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series B in April 2025, described as oversubscribed and led by Key1 Capital. This injection is framed as fuel for hiring, product expansion, and go‑to‑market activity.

Strategic Partnerships: Channel integrations such as Homethrive and availability within the PrismHR ecosystem, along with selections by platforms like Vensure and a collaboration with TriNet, expand distribution reach. These moves are presented as widening access to employers and SMBs through established ecosystems.

Innovation-Driven Growth: Product velocity includes launches like Healthee Connect in 2025 and new AI capabilities such as AI-powered Claims Analytics and “Zoe for HR” in 2026. This cadence signals continued investment beyond core benefits Q&A toward analytics and broader platform functionality.

Market Expansion: Geographic reach is presented as Medicare-covered virtual therapy available across all 50 states, with therapist-by-state listings that signal recent build-out. Statements about operating across many states and serving hundreds to thousands of patients reinforce an expanding footprint.

Strong Hiring & Retention: Active recruiting is visible via an Ashby-powered careers site with roles like a Founding Engineer and multiple remote therapist postings, alongside additional listings on job boards. LinkedIn shows a 51–200 employee range with 140+ listed profiles, consistent with team expansion.

Strategic Partnerships: A collaboration with Advanced Nursing & Home Care (January 2025) extends access through senior-care channels. In-network positioning with Medicare supports referral-driven growth among older adults.

Market Expansion: The company lists active provider availability across multiple states, claims nationwide service, and is actively recruiting clinicians in additional geographies. These signals indicate continued footprint growth beyond a single‑state presence.

Strategic Partnerships: The organization markets partnerships with schools, universities, physicians/health systems, and digital health platforms. This referral- and integration-led approach suggests scaling beyond direct-to-consumer channels.

Cost & Operational Efficiency: A technical case study describes rebuilt analytics enabling same‑day claims filing for most appointments with very high claims acceptance. These revenue-cycle improvements indicate maturing operations that can support scaling.